New drug could cut frequent blood draws for rare blood cancer patients

NCT ID NCT05143957

First seen Dec 12, 2025 · Last updated May 13, 2026 · Updated 30 times

Summary

This study tests a new drug called sapablursen in about 50 people with polycythemia vera, a rare blood cancer that causes too many red blood cells. The goal is to see if the drug can reduce how often patients need phlebotomy (removing blood) and improve their symptoms. Participants must currently rely on regular phlebotomy and may or may not have used other treatments before.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PHLEBOTOMY DEPENDENT POLYCYTHEMIA VERA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Border Medical Oncology Research Unit

    Albury, 2640, Australia

  • Calvary Mater Newcastle Hospital

    Waratah, New South Wales, 2298, Australia

  • Cleveland Clinic Foundation

    Cleveland, Ohio, 44195, United States

  • John Theurer Cancer Center

    Hackensack, New Jersey, 07601, United States

  • MICS Centrum Medyczne Toruń

    Torun, 87-100, Poland

  • Mayo Clinic Hospital

    Phoenix, Arizona, 85054, United States

  • McGill University Health Centre

    Montreal, Quebec, H4A 3J1, Canada

  • O'Neal Comprehensive Cancer Center University of Alabama at Birmingham

    Birmingham, Alabama, 35249, United States

  • Oxford University Hospitals NHS Foundation Trust

    Oxford, England, OX37LE, United Kingdom

  • Samodzielny Publiczny Szpital Kliniczny Nr 1 w Lublinie, Klinika Hematoonkologii i Transplantacji Szpiku

    Lublin, 20-081, Poland

  • University College London Hospitals NHS Foundation Trust

    London, NW1 2PG, United Kingdom

  • University of Texas MD Anderson Cancer Center

    Houston, Texas, 77030, United States

  • Wojewódzki Szpital Specjalistyczny Sp. z o.o.

    Słupsk, 76-200, Poland

Conditions

Explore the condition pages connected to this study.